Member Info for The_Paladin

Semantic.

The issue in question is not the recent volume of traded IBAI shares. It is the fact that, if we believe the information from the company, and there is no reason to dispute it, we should be faring a lot better than at present. The recent partnerships have set the company on the right track, but why isn’t our market leading technology achieving sales commensurate with its high quality?

I have been asking that question for a considerable amount of time. The company’s revenues do not match with the positive messages regularly posted on LinkedIn, X, and the company’s website?

That being said, I believe that the best is yet to come, starting with the summative results from the GaM trial. Let us see what happens?

My broker will buy up to 600K shares @ 0.931p. NT above that number.

I am happy to have been proven wrong yesterday. The share price appears to be settling in a new trading range? At least for the time being?

It is unfortunate that my mistrust in TEB remains, despite semantics’s attempts to draw a line under it. Our CEO can only restore trust through positive actions that will improve on the company’s current position. It is what good leaders do.

Not me Shmokenn. I respect everyone’s contribution, as long as it is sensible. Your statements are well inside this category.

Likewise, my response doesn’t arise from an emotional reaction. Nor am I an impatient investor. Far from it. However, I do not believe that it is unreasonable to be somewhat bewildered by this morning’s post -consolidation trading, especially as this round followed two positive RNS statements from the company this week?

“That’s what normally happens after consolidation.”

No it isn’t normal at all.

In general, stock consolidation (or reverse stock split) does not inherently cause a drop in share price; instead, it increases the per-share price by reducing the number of outstanding shares, without changing the overall value of a shareholder's holdings or the company's market capitalisation. However, a consolidation can be perceived negatively by investors as a sign of distress, potentially leading to future price declines if not accompanied by improvements in the company's performance.

In Capai’s case, the reason for consolidation has been thoroughly explained to, and accepted by investors. Moreover’s the two RNS messages issued this week should have added to investor confidence. It should not have resulted in this morning’s early share price action.

This is not a normal market fluctuation. Two positive RNS statements have already been issued this week. This morning’s drop already approaching 20% on the first post consolidation trading day appears to have been deliberately planned beforehand?

I am unhappy about this morning’s selling reducing the share price by > 10% from what was already a low trading range.

In recent days we have received two very positive RNS statements. Yet a seller persists, and sells 6 lots of 100K shares on the first day that trading has resumed following share price consolidation.

My response will be a top up when I am satisfied that a new floor has been reached. The most annoying feature of this share is that most investors could have increased their shareholdings considerably had they participated in the trading fiasco that has persisted for so many months. Well done anyone, who has managed to do just that.

When I invested, I did not expect linear growth. Far from it. However, the extent to which the shares of a potentially viable company have been traded is bizarre in my opinion.

The abrupt fall back on small volumes also reflects the “quality” of the recent RNS announcements. Both are indicative of the company’s potential. They don’t yet add any real value to IBAI.

IBAI will need to announce a considerable improvement in their revenue, or “breakthrough” news linked to the GaM trial before the share price rises to and stabilises at a higher level IMHO.

As I see it, we will initially need to await the publication of the summative results of the Ph I trial for a grounded upward shift in the share price? This might be followed by the company’s plans for a follow up Ph II trial? Additionally, it might be coupled with news of the awaited resubmission to the FDA? Both are reliant on the same analysed and evaluated data from the completed trial.

Unfortunately, IBAI investors like myself will need to be patient for longer until substantial news emerges. It is difficult to anticipate when this will happen. My best prediction is early next year - based on the limited available information?

Magic-orb. An honest post, and who could blame you? We all have our strategies, and if it works for the individual, they should continue to use them.

Personally, I am continuing to hold for the long term here. Unfortunately, I have suffered a huge loss elsewhere from holding, when I ought to have sold when a good profit was on offer. Greed does strange things to people. It won’t apply to me a second time.

I believe that Capai is a good investment for the longer term, as it is run by professional business people, who know exactly where they want to take this company. The potential for success is realistic, and I am as optimistic as I can be about any investment.

Good fortune everyone.

Thank you Phil.

As regards a timeline, the FDA submission update was on the 12th June. Following the subsequent trial soft close, teams from IBAI and MCW will have continued with upgrading existing data, and updating patient data as the trial draws to its targeted conclusion in December? Presumably, it wouldn’t be unreasonable to anticipate the re-submission of the FDA application sometime early next year?

Should this prove to be successful, perhaps larger enterprises will take notice and run a ruler over IBAI with a view to a partnership, or more probably better for them a buyout?

All blue sky thinking on my part, but who knows what the future holds for IB’s technology, and the company’s involvement in MCW’s GaM trial?

I agree Tyke. The share price has held well to date, but will inevitably drop, until further significant good news arrives. Short term traders are impatient, and on the look out for quick profits, and moving on to the next opportunities. If this works for them, who could blame them?

From my point of view, I have followed Phil’s advice, and viewed a lot of videos from the website links. The presentation/webinar on the GaM trial, although long was well worth watching.

I agree that some consolidation from TEB might be useful, perhaps on Proactive Investors? I am fairly sure that he will do just that when he has big news to announce. Would he end it in his best Robert Downey Jr (Tony Stark/Iron Man) voice with the words “I am semantic”?

It has been a neutral trading day, and I expect it to close near to last Friday’s closing price.

I am unconcerned about the post consolidation share price. It is the stream of announcements to follow in the coming months that will decide the course of the share price.

It may well take longer than some investors anticipate? I am more or less convinced that in at year’s time, the share price will be considerably higher than it is today.

Better than I expected, so far today. Earlier, it was a case of negotiated trades, even on tiny trades. Currently, I

1m shares can be sold @ 0.905p.

I view our current position as baby steps in the right direction. Partnerships have been established both on the imaging side, and linked to GaM’s potential in treating a range of tumours, in individualised combinational patient therapies. There is a lot of further work to be completed. Perhaps the next announcement will be about the analysis and evaluation of the Ph1 GliB trial, and the next steps?

Like many investors here, I have held and added for several years. It is still a matter of being patient and seeing what happens next?

My broker is still buying - up to 600K shares. NT above that number.

0.581p per share for 600K shares; 0.6251p per share for 100K shares or fewer.

The share price remains at these derisory levels in the absence of news.

Approximately 0.51285% of the company's shares bought so far today with no shift in the share price? When just over 1m shares were sold recently, the sale was accompanied by a 3.85% drop in the share price?

I watched Dr. Connolly's Proactive Investors interview earlier today. She has a team who are analysing brain tissue samples of patients at various stages of their GaM treatment. This is to enable detailed planning of a Ph II trial. Although the summative results of the Ph I trial haven't been published, the treatment with the product at increasing doses have demonstrated no ill effects. Isn't this the main purpose of a Ph1 trial i.e. to confirm the patients' tolerance of the product at the requisite dose? Additionally the efficacy results to date show promise, and Dr.Connolly's mentioned that the treatment could be trialled with other forms of cancer. Is this announcement, when it arrives, the breakthrough that IB investors have been waiting for?

MS has correctly IMHO substituted regular IBAI updates to keep interested parties involved, in place of the previous newsletters.

https://us20.campaign-archive.com/home/?u=ee2fb759d033ff87132180f83&id=65678679bc

I still don’t understand why QSMetric are working with IBAI to proliferate their technologies? Is it a case of two heads being better than one? Could this development, which MS announced enthusiastically, work for the mutual benefit of both companies?

https://mailchi.mp/imagingbiometrics/answer-your-most-important-questions-18158140

CellularKing’s post is diametrically opposite to the message he last posted on this forum. Further evidence that traders are playing their part in the ongoing share price fluctuations.

When serious news emerges, sooner or later but inevitably, there will be less of the obvious ramping and de-ramping from traders.

We all have our strategies, trading being one of them, although no one should take a fellow investor on a bulletin board’s comments too literally. Everyone should decide for themselves how they proceed with their investments.

It is likely that the two early trades are buys. My broker’s sell price is a miserly 0.611p for 250K shares. They will still accept 1m shares at 0.6066p per share. This suggests that there may be a buyer or buyers currently establishing a position? Alternatively at the all time low range we find ourselves in, it might be traders looking for a quick profit?

We are unfortunately in having a BOD who appear to be reluctant to achieve anything from IB’s market leading products? Surely if IB’s technology is as powerful as they claim, and there is no reason to doubt them, there must be a large entity out there who could market their products to optimum effect? It is a kind of “dog in a manger” attitude they are showing.

Perhaps they are waiting for the re-submission of the GaM Ph1 trial results to the FDA? This would have the additional benefit of showcasing the quality of their technologies in addition to demonstrating the efficacy of the GaM treatment with a small number of of GliB patients? All supposition on my part. I seem to be more enthusiastic about IB’s technology than the BOD at the present time.

A flurry of pointless small trades so far today. Interestingly, my broker would buy 1m IBAI shares at the all time low price of 0.556p.

There is no reassurance in this, however. Most probably a trader hoping to buy at a rock bottom price to achieve a quick profit? We are not part of the AIM market, but this sort of activity is prevalent on AIM , virtually on a daily basis.